Properly Substituted Cyclic Bis-(2-bromobenzylidene) Compounds Behaved as Dual p300/CARM1 Inhibitors and Induced Apoptosis in Cancer Cells.
Rossella Fioravanti, Stefano Tomassi, Elisabetta Di Bello, Annalisa Romanelli, Andrea Maria Plateroti, Rosaria Benedetti, Mariarosaria Conte, Ettore Novellino, Lucia Altucci, Sergio Valente and 1 more
Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 8 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 3 institutions in 1 country.
Rossella FioravantiDipartimento di Chimica e Tecnologie del Farmaco, 'Sapienza' Università di Roma, 00185 Roma, Italy.
Stefano TomassiDipartimento di Farmacia, Università di Napoli 'Federico II', 80131 Napoli, Italy.
Elisabetta Di BelloDipartimento di Chimica e Tecnologie del Farmaco, 'Sapienza' Università di Roma, 00185 Roma, Italy.
Annalisa RomanelliDipartimento di Chimica e Tecnologie del Farmaco, 'Sapienza' Università di Roma, 00185 Roma, Italy.
Andrea Maria PlaterotiDipartimento di Neuroscienze, Salute Mentale e Organi di Senso-Nesmos, 'Sapienza' Università di Roma, 00185 Roma, Italy.
Rosaria BenedettiDipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, 80138 Napoli, Italy.ORCID 0000-0001-5517-5519
Mariarosaria ConteDipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, 80138 Napoli, Italy.
Ettore NovellinoDipartimento di Farmacia, Università di Napoli 'Federico II', 80131 Napoli, Italy.
Lucia AltucciDipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, 80138 Napoli, Italy.ORCID 0000-0002-7312-5387
Sergio ValenteDipartimento di Chimica e Tecnologie del Farmaco, 'Sapienza' Università di Roma, 00185 Roma, Italy.ORCID 0000-0002-2241-607X
Antonello MaiDipartimento di Chimica e Tecnologie del Farmaco, 'Sapienza' Università di Roma, 00185 Roma, Italy.ORCID 0000-0001-9176-2382
Sapienza University of Rome · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Naples Federico II · IT
Funding
Associazione Italiana per la Ricerca sul Cancro IG19162 and IG17217Campania Regional Government FASE2 IDEALEuropean Cooperation in Science and Technology EPICHEMBIO CM1406FP7 Health Blueprint 282510Ministero della Salute PE-2013-02355271Ministero dell'Istruzione, dell'Università e della Ricerca EPIGEN-MIUR-CNRMinistero dell'Istruzione, dell'Università e della Ricerca POC01_00043Ministero dell'Istruzione, dell'Università e della Ricerca PRIN2016-20152TE5PK_004POR Campania FSE 2014-2020 ASSE IIIVALERE iCUREVALERE 2019 Program id:415, Merit Ranking Area ERC LS
6 · The paper itself
Abstract
Bis-(3-bromo-4-hydroxy)benzylidene cyclic compounds have been reported by us as epigenetic multiple ligands, but different substitutions at the two wings provided analogues with selective inhibition. Since the 1-benzyl-3,5-bis((
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Properly Substituted Cyclic Bis-(2-bromobenzylidene) Compounds Behaved as Dual p300/CARM1 Inhibitors and Induced Apoptosis in Cancer Cells. · full record | OpenQuestion